Bayer ordered to pay $2.25B after jury finds Roundup weed killer caused Pennsylvania man’s cancer

A Pennsylvania man who said Bayer's Roundup weed killer caused his cancer was awarded $2.25 billion by a Philadelphia jury.

John McKivison, 49, was diagnosed with non-Hodgkin’s lymphoma "after using Roundup on his property for 20 years," his attorneys, Tom Kline and Jason Itkin, said in a joint statement. He sued Monsanto Co., which is owned by Bayer, in the Philadelphia Court of Common Pleas.

On Friday, the jury handed down the verdict, which includes $2 billion in punitive damages.

"The jury's unanimous verdict was a condemnation of 50 years of misconduct by Monsanto and a declaration that its misconduct was in reckless disregard of human safety and a substantial cause of John McKivison's cancer," Kline and Itkin said.

They said the award amount "sends a clear message that this multi-national corporation needs top to bottom change."

Bayer said it disagreed with the verdict and believes it has "strong arguments on appeal to get this verdict overturned and the unconstitutionally excessive damage award eliminated or reduced."

"While we have great sympathy for the plaintiff in this case, we are confident that our products can be used safely and are not carcinogenic, consistent with the assessments of expert regulators worldwide," it said.

For Subscribers

FOR SUBSCRIBERSAbdul El-Sayed tries to woo MAHA voters as Democrats seek inroads with RFK’s supporters

FOR SUBSCRIBERSGOP super PAC increases its spending for Sen. Jon Husted in tough Ohio race

FOR SUBSCRIBERSKratom-like substances are popping up in a typically benign supplement

FOR SUBSCRIBERSRecords reveal tumultuous marriage between killed New York Times executive and wife

FOR SUBSCRIBERSFrom clean energy warrior to ‘wall of shame,’ James Talarico reverses on a fossil fuel money pledge

FOR SUBSCRIBERSCongressional staff planned official trip with luxury stops in Italy and France weeks before election

FOR SUBSCRIBERSA harrowing ordeal aboard an Israel-bound plane

FOR SUBSCRIBERSOpenAI CEO Sam Altman to skip congressional hearing on rogue AI agents

FOR SUBSCRIBERSKey DOJ lawyers departed Trump ‘grand conspiracy’ probe amid pressure to produce, source says

FOR SUBSCRIBERSTrump’s new AI chatbot often links to a site launched under Clinton 26 years ago

FOR SUBSCRIBERSAt MAHA summit, industry CEOs the movement once vilified take the stage

FOR SUBSCRIBERSThis Paralympian has two goals: Win medals and give away $500,000 to her teammates

FOR SUBSCRIBERSCornell rape allegation spotlights stringent New York state laws that have long drawn criticism

FOR SUBSCRIBERSThe debate over AI’s future rages on both coasts

FOR SUBSCRIBERSDecades-old march dispute reignites in Northern Ireland, threatening political crisis

Several cancer patients and their estates have sued the company, including a man in California who was awarded $332 million and a man in Philadelphia who was awarded $175 million. Bayer has said it will appeal both verdicts.

For Subscribers

FOR SUBSCRIBERSAbdul El-Sayed tries to woo MAHA voters as Democrats seek inroads with RFK’s supporters

FOR SUBSCRIBERSGOP super PAC increases its spending for Sen. Jon Husted in tough Ohio race

FOR SUBSCRIBERSKratom-like substances are popping up in a typically benign supplement

FOR SUBSCRIBERSRecords reveal tumultuous marriage between killed New York Times executive and wife

FOR SUBSCRIBERSFrom clean energy warrior to ‘wall of shame,’ James Talarico reverses on a fossil fuel money pledge

FOR SUBSCRIBERSCongressional staff planned official trip with luxury stops in Italy and France weeks before election

FOR SUBSCRIBERSA harrowing ordeal aboard an Israel-bound plane

FOR SUBSCRIBERSOpenAI CEO Sam Altman to skip congressional hearing on rogue AI agents

FOR SUBSCRIBERSKey DOJ lawyers departed Trump ‘grand conspiracy’ probe amid pressure to produce, source says

FOR SUBSCRIBERSTrump’s new AI chatbot often links to a site launched under Clinton 26 years ago

FOR SUBSCRIBERSAt MAHA summit, industry CEOs the movement once vilified take the stage

FOR SUBSCRIBERSThis Paralympian has two goals: Win medals and give away $500,000 to her teammates

FOR SUBSCRIBERSCornell rape allegation spotlights stringent New York state laws that have long drawn criticism

FOR SUBSCRIBERSThe debate over AI’s future rages on both coasts

FOR SUBSCRIBERSDecades-old march dispute reignites in Northern Ireland, threatening political crisis

In 2015, the World Health Organization's International Agency for Research on Cancer released a report suggesting glyphosate, the key ingredient in Roundup, is "probably carcinogenic to humans."

Years later, the U.S. Environmental Protection Agency said it "found that there are no risks of concern to human health when glyphosate is used in accordance with its current label" and is "unlikely to be a human carcinogen."

"EPA did not agree with the International Agency for Research on Cancer (IARC) conclusion that glyphosate is 'probably carcinogenic to humans,'" the agency wrote. "EPA considered a significantly more extensive and relevant dataset than the International Agency on the Research for Cancer (IARC). EPA’s database includes studies submitted to support registration of glyphosate and studies EPA identified in the open literature."